Fig. 3

Selection of first-line AD therapy for drug-naive patients with T2DM in the outpatient setting. AD antidiabetes drugs, DPP-4 dipeptidyl peptidase-4, GI glucosidase inhibitor, GLP-1 RA glucagon like peptide-1 receptor agonist, SGLT-2 sodium glucose co-transporter-2, SU sulfonylurea, T2DM type 2 diabetes mellitus, TZD thiazolidinediones